10-Q: Bolt Projects Holdings Faces Delisting Amid Liquidity Woes

Bolt Projects Holdings, Inc. reported a significant increase in Q2 2025 revenue but faces substantial doubt about its ability to continue as a going concern and a Nasdaq delisting notice.

Summary

• Revenue for the three months ended June 30, 2025, increased by $1.2 million (2,225%) to $1.302 million, primarily due to increased sales of Vegan Silk Technology Platform products.
• Gross income improved to $0.06 million for Q2 2025, from a gross loss of $0.03 million in Q2 2024, attributed to reduced material costs and pricing discipline.
• Net loss for the six months ended June 30, 2025, significantly decreased to $10.542 million from $65.526 million in the prior year period, an 84% reduction.
• Cash used in operating activities for the six months ended June 30, 2025, decreased to $2.856 million from $7.362 million in the prior year.
• As of June 30, 2025, cash and cash equivalents totaled $0.974 million, with an accumulated deficit of $472.343 million and negative net working capital of $5.5 million.
• The company received a notice of delisting determination from Nasdaq on August 12, 2025, for non-compliance with minimum Market Value of Listed Securities and Publicly Held Shares requirements, and intends to appeal.
• A non-binding term sheet for up to $20 million in financing (preferred stock and equity line of credit) was signed with Ascent Partners LLC on June 27, 2025, with the first tranche planned for September 2025, pending shareholder approval.
• An excise tax liability of approximately $2.9 million remains outstanding as of June 30, 2025, subject to additional interest and penalties.

Sentiment

Score: 3

Explanation: While the company shows significant revenue growth and reduced net loss, its severe liquidity issues, ongoing going concern doubt, and Nasdaq delisting threat overshadow these improvements. The reliance on future financing and a single customer/manufacturer adds substantial risk, leading to a very cautious outlook despite operational improvements.

Positives

• Significant revenue growth of 2,225% for Q2 2025 and 1,864% for H1 2025, driven by increased sales of Vegan Silk Technology Platform products.
• Improvement in gross income, moving from a loss of $0.03 million in Q2 2024 to a gain of $0.06 million in Q2 2025, due to reduced material costs and pricing discipline.
• Substantial reduction in net loss by 84% for the six months ended June 30, 2025, compared to the same period in 2024.
• Reduced cash burn from operating activities, decreasing by $4.5 million for the six months ended June 30, 2025, compared to the prior year.
• Successful regaining of Nasdaq minimum bid price compliance following a 1-for-20 reverse stock split.
• Secured a non-binding term sheet for up to $20 million in financing with Ascent Partners LLC, indicating potential future capital infusion.
• Resolution of Private Placement Warrants through exchange for Sponsor Warrants with a lower exercise price ($10.00 vs $230.00).

Negatives

• The company has a history of losses and negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern.
• Current cash and cash equivalents of $0.974 million as of June 30, 2025, are insufficient to fund operating, investing, and financing needs for the next twelve months.
• Accumulated deficit increased to $472.343 million as of June 30, 2025.
• The company has a negative net working capital of $5.5 million.
• Received a notice of delisting determination from Nasdaq on August 12, 2025, for failing to meet minimum Market Value of Listed Securities and Publicly Held Shares requirements.
• Outstanding excise tax liability of approximately $2.9 million as of June 30, 2025, subject to additional interest and penalties due to non-payment.
• High customer concentration, with a single customer accounting for 95% of total revenue in Q2 2025 and 94% in H1 2025.
• Reliance on a single manufacturing partner, Laurus Bio, for Vegan Silk Technology products, posing supply chain risk.
• Identified material weaknesses in internal control over financial reporting.

Risks

• History of losses and negative cash flows from operations, and the need for substantial capital raise substantial doubt about the ability to continue as a going concern.
• Inability to generate sufficient cash to service debt obligations, potentially forcing other actions that may not be successful.
• Failure to meet Nasdaq continued listing requirements could result in delisting of Common stock.
• Significant future expenses and capital expenditures to execute the business plan, with potential inability to control expenses or raise additional capital on favorable terms.
• Revenue is primarily generated from sales of the Vegan Silk Technology Platform, making the company highly dependent on its success.
• Vegan Silk Technology Platform has limited product and brand recognition within the beauty and personal care market as a substitute for silicone elastomers.
• Vegan Silk Technology Platform and future biomaterial product candidates may not achieve market success, potentially preventing significant revenue generation.
• Reliance on a single manufacturing partner and facility (Laurus Bio) for production, and future reliance on a small number of partners, poses supply chain risks.
• A limited number of customers, distributors, and collaboration partners account for a material portion of revenue, and their loss could harm operating results.
• Certain contracts granting exclusivity rights to customers may limit the ability to sell products in certain markets.
• Substantial competition from incumbent materials and other new entrants, with risk of failing to develop innovative products or scale production.
• Identified material weaknesses in internal control over financial reporting, which if not remediated, could adversely affect accurate and timely financial reporting and investor confidence.
• Inability to adequately protect patents and other intellectual property assets, which could affect competitive position and product value, and costly litigation.
• Reliance on trade secrets to protect technology, with failure to maintain protection limiting ability to compete.
• Unfavorable macroeconomic conditions (inflation, interest rates, trade relations) could negatively affect business growth and ability to obtain financing.

Future Outlook

The company anticipates needing additional capital to fund its operations and product development, with current cash resources insufficient for the next twelve months. It expects to secure financing through additional customer contracts, restructuring current equity instruments and financial obligations, and completing anticipated financing activities in Q3 2025, including a non-binding term sheet for up to $20 million. The company is appealing a Nasdaq delisting determination and intends to present a compliance plan.

Management Comments

• Our existing cash resources will be sufficient to fund planned operations until we complete our anticipated financing activities in the third quarter of 2025, although there is no assurance that this financing will be consummated.
• We believe our future performance and success depends on, to a substantial extent, our ability to capitalize on the following opportunities, which in turn is subject to significant risks and challenges...
• We believe that we must continue to dedicate resources to research and development efforts to maintain a competitive position.
• We will continue to monitor the design and effectiveness of these and other processes, procedures, and controls and make any further changes management deems appropriate.

Industry Context

Bolt Projects Holdings operates in the biomaterials industry, specifically targeting the beauty and personal care market with its Vegan Silk Technology Platform (b-silk and xl-silk) as a biodegradable and vegan replacement for silicone elastomers. This positions the company within the growing trend of sustainable and natural ingredients in cosmetics and personal care products, aiming to disrupt traditional chemical-based formulations. The company's focus on a single platform technology suggests a strategy of deep specialization within this niche.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks.

Corporate Governance

Legal Proceedings

• Donoghue v. Golden Arrow Sponsor, LLC, Case No. 25-CV-5395-PKC, pending in the United States District Court for the Southern District of New York. The company is named as a nominal defendant in a lawsuit asserting claims under Section 16(b) of the Securities Exchange Act of 1934 against Golden Arrow Sponsor, LLC, related to transactions involving the company's securities. The company has not been accused of wrongdoing and is cooperating with legal counsel.

Related Party Transactions

• Settlement Agreement and Exchange Agreement entered into on February 14, 2025, with Golden Arrow Sponsor, LLC (a related party), regarding the $2.9 million excise tax liability. The Sponsor agreed to provide or organize $10.0 million in financing by August 13, 2025, or pay 75% of the outstanding excise tax liability. As partial consideration, the company exchanged Private Placement Warrants for Sponsor Warrants (250,000 shares at an exercise price of $10.00 per share).
• The Sponsor has agreed, with limited exceptions, not to transfer, assign, or sell any of its 352,375 shares of Common stock (Founder Shares) until the earlier of one year after the Merger completion or specific stock price/liquidation events.
• Remeasurement of related party private placement warrant liability resulted in a loss of $0.1 million for the six months ended June 30, 2025, reflecting changes in fair value of warrants issued to the Sponsor.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future capital raises (equity line of credit, convertible vendor payables). Risk of delisting from Nasdaq could severely impact liquidity and share value. Reverse stock split temporarily addressed bid price but did not fundamentally improve market value.
• Employees: Stock option repricing could improve the value of their equity awards. However, the company's going concern doubt and financial instability pose job security risks.
• Customers: High customer concentration means the loss of a major customer could severely impact revenue. The three-year supply agreement with a major customer provides some stability.
• Suppliers/Creditors: The agreement with Seneca to purchase vendor payables could provide some relief to certain vendors. The deferral of interest payments to Ginkgo Bioworks indicates financial strain that could affect other creditors. The unpaid excise tax liability also represents a significant outstanding obligation.

Next Steps

• Satisfy obligations related to the deferred June 30, 2025 interest payment for the Amended Senior Note by the earlier of the Seneca claims purchase agreement termination or August 31, 2025.
• Appeal the Nasdaq delisting determination to the Nasdaq Hearings Panel and present a compliance plan.
• Complete anticipated financing activities in Q3 2025, including the Ascent Partners LLC financing, which requires shareholder approval at the annual meeting on August 29, 2025.
• Sponsor to provide or organize $10.0 million in financing by August 13, 2025, or pay 75% of the outstanding excise tax liability.
• Continue efforts to remediate material weaknesses in internal control over financial reporting.
• Continue to increase sales of products to existing customers and obtain new customers.
• Continue investments in research and development efforts to maintain a competitive position.

Key Dates

Recommendation

Despite a notable increase in revenue and a reduction in net loss, the company faces severe liquidity challenges, with insufficient cash to fund operations for the next twelve months and substantial doubt about its ability to continue as a going concern. The recent delisting notice from Nasdaq for failing to meet market value requirements poses an immediate and significant threat to its public listing, which would severely impair liquidity and investor confidence. While there are ongoing efforts to secure financing and address the excise tax liability, the high customer concentration and reliance on a single manufacturing partner add further operational risks. The overall financial instability and the imminent delisting threat outweigh the positive revenue trends, suggesting a high-risk investment with significant downside potential.

Keywords

Biomaterials, Vegan Silk, Beauty and Personal Care, Silicone Elastomer Substitute, SEC Filing, 10-Q, Financial Results, Nasdaq Listing, Going Concern, Capital Raise, Biotechnology, Sustainable Materials, Bolt Projects Holdings